OneSource Specialty Pharma Q2 Results Drive 14% Stock Surge
OneSource Specialty Pharma shares jumped nearly 14% to a three-week high after reporting Q2 revenue growth of 37% and a massive year-on-year profit increase.

OneSource Specialty Pharma shares surged nearly 14% on October 27, hitting a three-week high of ₹1,589 apiece. The jump followed the company's second-quarter results, which showed revenue up 37% year-on-year and adjusted profit after tax soaring approximately 1,372%.
The stock's gain marked a sharp reversal from a 13% decline over the previous month. Since its listing in January 2025, the share price has experienced considerable volatility without a sustained trend. At a level of around ₹1,598, it remains nearly 29% below its listing-era highs but trades about 50% above its record low of ₹1,057. Volume was thin early in the session. The stock has risen around 4.5% so far in October, putting it on track for its biggest monthly gain in recent months.
Q2 Performance Highlights
Revenue for the quarter grew 37.4% year-on-year to ₹516.2 crore, a 15% increase from the previous quarter. Earnings before interest, taxes, depreciation, and amortization (EBITDA) rose 53% year-on-year and 32% sequentially to ₹163.3 crore. This performance represented the company's third consecutive quarter of sequential growth.
The company reported a consolidated net profit of ₹57.4 crore. On a standalone basis, net profit was ₹86.2 crore. Adjusted profit after tax, which excludes exceptional items, came in at ₹93.7 crore, compared to ₹6.37 crore in the same period last year. The two sets of figures were on different accounting bases and should not be compared line by line.
| Metric | Consolidated Q2 FY27 | Standalone Q2 FY27 |
|---|---|---|
| Revenue | ₹516.2 crore | Not specified |
| EBITDA | ₹163.2 crore | Not specified |
| Net Profit | ₹57.4 crore | ₹86.2 crore |
Consolidated EBITDA margin expanded to 31.6%. The standalone profit and EBITDA figures were sourced from market data, while the consolidated figures came from a results summary.
Growth Trajectory and Outlook
Management, led by CEO and Managing Director Neeraj Sharma, stated the performance demonstrated strong momentum. The company announced 12 new product launches during the quarter. It also maintained its financial year 2028 guidance, targeting $400 million in organic revenue and a steady-state EBITDA margin of 40%.
OneSource stated its drug delivery device (DDD) capacity is expected to triple by FY28. This expansion is based on two cartridge lines beginning commercial operations and the factory acceptance test for a third line being completed. The company's stated FY28 guidance of $400 million in organic revenue and 40% EBITDA margin remains the key forward-looking metric.





